Share
Dr. Eric A. Hughes
Monte Rosa Therapeutics, a clinical-stage biotechnology company pioneering molecular glue degrader (MGD)-based medicines, has appointed Eric A. Hughes, M.D., Ph.D., to its Board of Directors. Dr. Hughes, currently Executive Vice President, Global R&D, and Chief Medical Officer at Teva Pharmaceuticals, brings decades of leadership experience in biopharmaceutical R&D, clinical development, and translational medicine.
Prior to Teva, Dr. Hughes served as Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals. He previously held key leadership roles at Novartis, including Global Development Unit Head for Immunology, Hepatology, and Dermatology, and at Bristol Myers Squibb, where he oversaw multiple therapeutic areas such as virology, fibrotic diseases, genetically defined diseases, autoimmunity, and cardiology.
During the COVID-19 pandemic, Dr. Hughes played a pivotal role as Co-Chair of the Therapeutics Clinical Working Group for the NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership.
Dr. Hughes earned his M.D. and Ph.D. from Yale School of Medicine and brings strategic expertise in drug development and translational research that will help advance Monte Rosa’s pipeline of precision-targeted therapeutics.
